INVO Bioscience, Inc. - 10-Q Summary (Q1 2011)
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2011. INVO Bioscience, Inc. is a development-stage company focused on the manufacture and sale of the INVOcell device, an assisted reproductive technology designed to provide an affordable alternative to in vitro fertilization (IVF). The company holds CE marking for distribution in the European Economic Area and various other international markets but is seeking FDA clearance for the U.S. market. As of the reporting date, the company has generated minimal revenue and sustained significant losses since inception.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Product Revenue | $33,059 | $26,820 |
| Gross Margin | $26,833 (81%) | $18,498 (69%) |
| Net Loss | $(198,825) | $870,568 (Income) |
| Cash and Equivalents | $5,157 | $3,661 |
| Working Capital Deficiency | $(2,700,162) | $(2,563,462) |
| Total Liabilities | $2,787,258 | $2,662,905 |
| Stockholders' Deficiency | $(2,662,119) | $(2,481,909) |
Cash Flow: Net cash used in operating activities was $63,134. Net cash provided by financing activities was $55,766, primarily from the issuance of common stock and convertible notes.
Material Changes vs. Prior Period
- Revenue Growth: Product revenue increased by approximately 23% compared to Q1 2010, driven by reorders from existing doctors and new customers.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased significantly by 55% (from $446,627 to $200,954). This reduction was due to lower legal fees, reduced investor awareness costs, and employees deferring salaries.
- Net Income Volatility: The company reported a net loss of $198,825 in Q1 2011, a stark contrast to the net income of $870,568 in Q1 2010. The prior year's income was largely driven by a non-cash gain of $1.35 million from the revaluation of derivative liabilities, which did not recur in the current period.
- Liquidity: Cash on hand remains critically low at $5,157, despite a slight increase from the prior quarter.
Outlook, Risks, and Contingencies
Going Concern: The filing explicitly states that the company's recurring losses, negative cash flows, and working capital deficiency raise substantial doubt about its ability to continue as a going concern. Continued operations are dependent on raising additional capital.
Capital Needs: Management estimates a monthly burn rate of approximately $175,000. The company is actively seeking funding through a Reserve Equity Financing Agreement (REF) with AGS Capital Group (up to $10 million) and private placements. However, the company cannot currently draw down on the REF until specific SEC filing updates are completed.
Regulatory Status: The company is pursuing FDA 510(k) clearance for the U.S. market, which requires a clinical trial estimated to cost $1 million. International sales remain the only current revenue source.
Legal Proceedings: The company is defending against a lawsuit filed by former employees and an investor of Medelle Corporation regarding the sale of assets. While claims against the company and CEO were dismissed in November 2010, claims against the President/CSO regarding fraud and breach of fiduciary duty remain pending. No loss has been accrued as the company believes the claims are baseless.
Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of March 31, 2011, due to limited resources and a lack of segregation of duties.
Investor Verification Checklist
- Cash Runway: Verify the immediate ability to fund operations given the $5,157 cash balance and $175,000 monthly burn rate.
- Capital Raise Status: Confirm the status of the SEC Post-Effective Amendment required to access the $10 million AGS Capital line of credit.
- Derivative Liabilities: Review the $180,000 derivative liability and the impact of stock price volatility on future earnings.
- Legal Exposure: Monitor the outcome of the remaining fraud and fiduciary duty claims against Dr. Claude Ranoux.
- Revenue Sustainability: Assess the durability of the 23% revenue increase given the company's reliance on international markets and limited marketing budget.